Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04970056 · ClinicalTrials.gov registry record

Pancreatic Cancer Early Detection Consortium

A clinical trial of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer, sponsored by Arbor Research Collaborative for Health.

Recruiting
Registry status
20,000
Enrollment target
20
Study locations

NCT04970056 is a study of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer that is actively recruiting participants, run by Arbor Research Collaborative for Health. The registered enrollment target is 20,000 participants, above the 363-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (5410% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04970056, a study of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer, is actively recruiting participants, sponsored by Arbor Research Collaborative for Health.

RECRUITING
Registry status
20,000 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Conditions Studied

Pancreatic Ductal Adenocarcinoma Pancreas Cancer Genetic Predisposition Pancreas Cyst

Study Locations (20)

California

  • Providence Health and Services - Burbank
  • City of Hope - Duarte
  • UC San Diego Moores Cancer Center - La Jolla
  • Cedars-Sinai Medical Center - Los Angeles
  • UCLA Health - Los Angeles
  • Hoag - Newport Beach
  • UC Irvine Health - Orange
  • UC Davis - Sacramento
  • University of California, San Francisco (UCSF) - San Francisco

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • University of Miami - Miami
  • Moffitt Cancer Center - Tampa

Illinois

  • Illinois CancerCare - Bloomington
  • University of Chicago Medicine - Chicago
  • NorthShore University HealthSystem - Evanston

Arizona

  • Mayo Clinic Arizona - Phoenix
  • Honor Health Research Institute - Scottsdale

Connecticut

  • Yale University - New Haven

Georgia

  • Emory University Hospital - Atlanta

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 20,000 participants
Start Date 2020-09-18
Est. Completion 2030-12-31

Sponsor

Arbor Research Collaborative for Health

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04970056

The ClinicalTrials.gov registry entry for NCT04970056 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 363-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (5410% higher). The listed sponsor is Arbor Research Collaborative for Health, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT04970056 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT04970056 about?

NCT04970056 is a clinical study titled "Pancreatic Cancer Early Detection Consortium". The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying ...

What is the current status of trial NCT04970056?

This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2020-09-18. Estimated completion is 2030-12-31.

What conditions does trial NCT04970056 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Genetic Predisposition, Pancreas Cyst.

Who is sponsoring clinical trial NCT04970056?

This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04970056 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Pancreas Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.